Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Regeneron Pharmaceuticals, Inc. (REGN) — XLV Health Care · S&P 500 Profile |再生元製藥公司介紹

health-careS&P500xlvxlv-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Regeneron Pharmaceuticals, Inc. (REGN) — Business, History & S&P 500 Profile | 再生元製藥公司介紹

Regeneron Pharmaceuticals, Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #123 · 再生元製藥公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 30, 2026 (ET) close
Financials: FY2025
MARKET CAP
$95.53B
Oct 30, 2026 close
S&P 500 WEIGHT
0.14%
Rank #123 · Oct 30, 2026
SECTOR RANK
#20
Health Care · Oct 30, 2026
S&P 500 RANK
#123
0.14% · Oct 30, 2026

SNAPSHOT

TickerREGN
CompanyRegeneron Pharmaceuticals, Inc.
GICS sector / industryHealth Care (XLV) / Biotechnology
S&P 500 rank (by weight)#123 · 0.14% (Oct 30, 2026)
Sector rank#20 in Health Care (Oct 30, 2026)
HeadquartersTarrytown, New York
Founded1988
CEOLeonard Schleifer (Co-founder and CEO)
Employees15,410
Market cap$95.53B (Oct 30, 2026)
Share price$927.89 (Oct 30, 2026)
SEC filingsEDGAR — CIK 0000872589

WHAT IT DOES

Regeneron Pharmaceuticals is a biotechnology company that discovers, invents and sells its own medicines, built on proprietary technology platforms rather than acquisitions. Its one-line model: turn in-house science — above all its VelociSuite antibody platforms and its genetics center — into patented drugs sold at specialty prices.

Revenue combines net product sales with collaboration revenue, mainly Regeneron's share of profits from its Sanofi partnership. In FY2025 collaboration revenue of $7.33B exceeded net product sales of $6.31B, so partner economics now matter as much as the company's own price tags.

The economics are those of a hit-driven drug developer: very high margins on successful antibodies, heavy and continuous R&D spending, and value concentrated in a few franchises — EYLEA in eye disease and Dupixent in immunology — whose patents and competition set the stock's story.

BUSINESS SEGMENTS

EYLEA franchiseAflibercept injections (EYLEA and EYLEA HD) for wet age-related macular degeneration, diabetic macular edema and other retinal diseases; first approved by the FDA in November 2011.
DupixentDupilumab for atopic dermatitis and other type 2 inflammatory diseases, developed and commercialized with Sanofi, which records global net sales; first approved in March 2017.
LibtayoCemiplimab, a PD-1 inhibitor for cutaneous squamous cell carcinoma and other cancers; first approved in September 2018.
Other marketed productsPraluent (cholesterol), Kevzara (rheumatoid arthritis), Arcalyst, Zaltrap, Inmazeb (Ebola) and Veopoz (CHAPLE disease), among others.
Platforms & geneticsThe VelociSuite technologies (including VelocImmune) that generate fully human antibodies, and the Regeneron Genetics Center, which has sequenced over 3 million exomes.

EYLEA franchise Aflibercept injections (EYLEA and EYLEA HD) for wet age-related macular degeneration, diabetic macular edema and other retinal diseases; first approved by the FDA in November 2011.

Dupixent Dupilumab for atopic dermatitis and other type 2 inflammatory diseases, developed and commercialized with Sanofi, which records global net sales; first approved in March 2017.

Libtayo Cemiplimab, a PD-1 inhibitor for cutaneous squamous cell carcinoma and other cancers; first approved in September 2018.

Other marketed products Praluent (cholesterol), Kevzara (rheumatoid arthritis), Arcalyst, Zaltrap, Inmazeb (Ebola) and Veopoz (CHAPLE disease), among others.

Platforms & genetics The VelociSuite technologies (including VelocImmune) that generate fully human antibodies, and the Regeneron Genetics Center, which has sequenced over 3 million exomes.

HISTORY

YearMilestone
1988Leonard Schleifer and George Yancopoulos found Regeneron in New York, focused on neurotrophic factors and regenerative medicine.
2011The FDA approves EYLEA (aflibercept) in November 2011; it becomes the company's first blockbuster.
2017The FDA approves Dupixent (dupilumab) in March 2017, opening the immunology franchise built with Sanofi.
2020Regeneron's REGN-COV2 antibody cocktail receives FDA emergency use authorization for COVID-19 in November 2020.

COMPETITIVE POSITION

  • Dupixent's leadership in type 2 inflammation, shared with Sanofi, is the standout immunology growth asset in its class.
  • A discovery engine — VelociSuite plus a genetics center with over 3 million sequenced exomes — run for internal science rather than acquisitions.
  • EYLEA's installed base in retinal disease, defended against branded rivals and biosimilars, including through the higher-dose EYLEA HD.
  • Founder-led continuity: Schleifer and Yancopoulos have run the company and its science since 1988.
  • A 2010s track record ranked among the decade's best-performing US listed companies (a 1,457% total return, per Barron's).

FINANCIAL SNAPSHOT

Total revenue$14.34B (FY2025 total revenues)
Operating income$3.58B (FY2025 operating income)
Net income$4.50B (FY2025 net income)
Diluted EPS$41.48 (FY2025 diluted EPS)
Source: Regeneron fiscal 2025 Form 10-K (year ended December 31, 2025).

KEY RISKS

  • Franchise concentration: EYLEA and Dupixent supply the bulk of revenue and profit.
  • EYLEA erosion from biosimilars and rival brands as the retinal-disease market gets more crowded.
  • Partner dependence: Dupixent economics are shared with Sanofi, and its global sales are recorded by Sanofi.
  • Drug-pricing policy: US pricing pressure and government negotiation regimes can cap net prices.
  • Pipeline risk: late-stage trial readouts are binary, while R&D spending is committed years ahead of proof.

WHY IT MATTERS FOR THE S&P 500

Regeneron is a small-weight health-care constituent: rank #123 by weight at 0.14% as of Oct 30, 2026, and #20 in Health Care. Its results are read as a gauge of specialty-drug pricing power and of how far a science-led, acquisition-free biotech model can scale.

SOURCES & METHODOLOGY

Financials, segments, headquartersRegeneron fiscal 2025 Form 10-K (year ended December 31, 2025)
Index weight & ranksSlickcharts S&P 500 weights, Oct 30, 2026 close, fetched Oct 31, 2026 (dispatch baseline, used verbatim)
Market cap$95.53B (Oct 30, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

The chart plots 119 monthly bars from Nov 2016 to Sep 2026. The window's monthly high was $1,211.20 in Aug 2024 and its low $271.37 in Sep 2019; Sep 2026 closed at $758.27.

REGN

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號REGN
公司Regeneron Pharmaceuticals, Inc.(再生元製藥)
GICS 板塊/行業醫療保健(XLV)/生物科技
標普500排名(按權重)#123 · 0.14%(Oct 30, 2026)
板塊內排名醫療保健 #20(Oct 30, 2026)
總部美國紐約州塔里敦
成立1988年
執行長Leonard Schleifer(共同創辦人兼執行長)
員工15,410
市值$95.53B(Oct 30, 2026)
股價$927.89(Oct 30, 2026)
SEC 申報EDGAR — CIK 0000872589

業務概覽

再生元製藥是一家生物科技公司,自行發現、發明並銷售藥物,依靠自有技術平台而非收購成長。其一句話商業模式是:把內部科學——尤其是 VelociSuite 抗體平台與基因中心——轉化為以專科藥價格出售的專利藥物。

收入由淨產品銷售與合作收入組成,合作收入主要為與 Sanofi 夥伴關係的利潤分成。FY2025 合作收入 73.3 億美元,已超過淨產品銷售 63.1 億美元,夥伴經濟學的重要性已不下於公司自身的定價。

其經濟學是爆款藥驅動的藥物開發模式:成功抗體藥毛利極高,研發投入沉重而持續,價值集中於少數旗艦產品——眼科的 EYLEA 與免疫的 Dupixent——其專利與競爭決定股價故事。

業務板塊

EYLEA 系列阿柏西普注射劑(EYLEA 與 EYLEA HD),用於濕性老年黃斑部病變、糖尿病黃斑水腫及其他視網膜疾病;2011 年 11 月首獲 FDA 批准。
Dupixent度匹魯單抗,用於異位性皮膚炎及其他第二型炎症疾病,與 Sanofi 共同開發及商業化,全球淨銷售由 Sanofi 入帳;2017 年 3 月首獲批准。
Libtayo西米普利單抗,PD-1 抑制劑,用於皮膚鱗狀細胞癌及其他癌症;2018 年 9 月首獲批准。
其他上市產品Praluent(膽固醇)、Kevzara(類風濕性關節炎)、Arcalyst、Zaltrap、Inmazeb(伊波拉)與 Veopoz(CHAPLE 病)等。
平台與基因VelociSuite 技術(包括 VelocImmune)用於生成全人源抗體;再生元基因中心已完成逾 300 萬個外顯子定序。

EYLEA 系列 阿柏西普注射劑(EYLEA 與 EYLEA HD),用於濕性老年黃斑部病變、糖尿病黃斑水腫及其他視網膜疾病;2011 年 11 月首獲 FDA 批准。

Dupixent 度匹魯單抗,用於異位性皮膚炎及其他第二型炎症疾病,與 Sanofi 共同開發及商業化,全球淨銷售由 Sanofi 入帳;2017 年 3 月首獲批准。

Libtayo 西米普利單抗,PD-1 抑制劑,用於皮膚鱗狀細胞癌及其他癌症;2018 年 9 月首獲批准。

其他上市產品 Praluent(膽固醇)、Kevzara(類風濕性關節炎)、Arcalyst、Zaltrap、Inmazeb(伊波拉)與 Veopoz(CHAPLE 病)等。

平台與基因 VelociSuite 技術(包括 VelocImmune)用於生成全人源抗體;再生元基因中心已完成逾 300 萬個外顯子定序。

歷史沿革

年份里程碑
1988Leonard Schleifer 與 George Yancopoulos 在紐約創立再生元,專注神經營養因子與再生醫學。
2011FDA 於 2011 年 11 月批准 EYLEA(阿柏西普),成為公司的首個重磅產品。
2017FDA 於 2017 年 3 月批准 Dupixent(度匹魯單抗),開啟與 Sanofi 合作的免疫業務。
2020再生元的 REGN-COV2 抗體雞尾酒療法於 2020 年 11 月獲 FDA 緊急使用授權用於 COVID-19。

競爭地位

  • Dupixent 在第二型炎症領域的領導地位(與 Sanofi 共享),是同類中最突出的免疫成長資產。
  • 發現引擎——VelociSuite 加上已定序逾 300 萬外顯子的基因中心——用於內部科學而非收購。
  • EYLEA 在視網膜疾病的既有基礎,以高劑量 EYLEA HD 等手段抵禦品牌藥與生物相似藥競爭。
  • 創辦人持續領導:Schleifer 與 Yancopoulos 自 1988 年起一直主持公司與其科學。
  • 2010 年代的回報位列美國上市公司最佳之列(據 Barron's,總回報 1,457%)。

財務快照

總收入$14.34B(FY2025 總收入)
營業利潤$3.58B(FY2025 營業利潤)
淨利潤$4.50B(FY2025 淨利潤)
稀釋 EPS$41.48(FY2025 稀釋 EPS)
來源:再生元製藥 2025 財年 Form 10-K(截至 2025 年 12 月 31 日)。

主要風險

  • 旗艦集中:EYLEA 與 Dupixent 佔收入與利潤的大部分。
  • EYLEA 受侵蝕:視網膜疾病市場日趨擁擠,生物相似藥與競爭品牌藥持續進逼。
  • 夥伴依賴:Dupixent 的經濟利益與 Sanofi 共享,其全球銷售由 Sanofi 入帳。
  • 藥價政策:美國藥價壓力與政府議價制度可壓低淨價格。
  • 管線風險:後期試驗結果具二元性,而研發支出在驗證前多年已須投入。

對標普500的重要性

再生元製藥是權重較小的醫療保健成分股:按權重排名 #123,權重 0.14%(以 Oct 30, 2026 為準),醫療保健板塊內排名 #20。其業績被視為專科藥定價能力,以及科學主導、不靠收購的生技模式能走多遠的指標。

來源與方法

財務、板塊、總部再生元製藥 2025 財年 Form 10-K(截至 2025 年 12 月 31 日)
指數權重與排名Slickcharts 標普500權重,Oct 30, 2026 收盤,Oct 31, 2026 抓取(派工基線,原文引用)
市值$95.53B(Oct 30, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

本圖繪製 2016 年 11 月至 2026 年 9 月共 119 根月 K。期間月線最高 $1,211.20(2024 年 8 月)、最低 $271.37(2019 年 9 月);2026 年 9 月收於 $758.27。

REGN

來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · REGN
Data as of Oct 30, 2026 · Financials FY2025 (10-K) · Market data Oct 2026
Previous · Marsh McLennan (MRSH) — XLF Financials · S&P 500 Profile |達信公司介紹Next · CSX Corporation (CSX) — XLI Industrials · S&P 500 Profile |CSX 公司公司介紹

Entered 2026-10-31 07:06 · updated 2026-11-14 23:58 · rev 6